Abstract:AIM:Point mutation, one of the commonest gene mutations, is the most important molecular pathogenesis of cancer and chronic infection. The commonest methods for detection of point mutation are based on polymerase chain reaction (PCR). These techniques, however, cannot be used in large scale screening since they are neither accurate nor simple. For this reason, this study established a novel method of competitively differentiated PCR (CD-PCR) for screening point mutation in clinical practice.METHODS:Two competitively differentiated primers for mutant-type and wild-type templates respectively with an identically complemented region in 3' end except for last 2 base pairs and a different non-complemented region in 5' end were designed. Thus, competitive amplification might be carried out at a lower annealing temperature at first, and then differentiated amplification at a higher annealing temperature when primers could not combine with initial templates. The amplification was performed in one-tube. The products of CD-PCR were detected using microplate hybridization assay. CD-PCR was evaluated by detecting G1896A variant of hepatitis B virus (HBV) in form of recombinant plasmids and in sera from patients with hepatitis B, and compared with allele-specific PCR (AS-PCR) and competitive AS-PCR.RESULTS:CD-PCR was successfully established. It could clearly distinguish wild-type and mutant-type plasmid DNA of G1896A variant when the amount of plasmid DNA was between 10(2)-10(8)copies/reaction, while for AS-PCR and competitive AS-PCR, the DNA amount was between 10(2)-10(4)copies/reaction. CD-PCR could detect one copy of G1896A variant among 10-100 copies of wild-type plasmid DNA. The specificity of CD-PCR was higher than those of AS-PCR and competitive AS-PCR in the detection of HBV G1896A variant in sera from patients with hepatitis B. CD-PCR was independent of the amount of HBV DNA in serum. HBV G1896A variant was more often found in HBeAg (-) patients with a lower level of detectable viremia than that with a higher level of detectable viremia (P=0.0192).CONCLUSION:CD-PCR is more specific since it is less influenced by the amount of initial templates and the cross amplification between mutant- and wild-type amplified products. It is also simple and time-saving. Thus, CD-PCR might be useful in routine gene typing and point mutation screening. HBV G1896A or other more important mutations have to be routinely detected in patients with a detectable level of viremia after HBeAg/antibody conversion in clinical practice.

Detection and RFLP Analysis of the Polymerase Gene Mutation of HBV DNA

Detection and Analysis of Gene Mutation of HBV DNA

Analysis of suspicious results of serum HBV DNA detected by fluorescence quantitative PCR

Detecting of the Hepatic Fibrotic Indexes and Serous Markers from Patients with Chronic Hepatitis B (chb)and Variation of HBV DNA YMDD

[Study of gene chips in the detection of YMDD mutations in the region of HBV polymeras]

A Novel Method Based on Ligase Detection Reaction for Low Abundant YIDD Mutants Detection in Hepatitis B Virus

Detection of YMDD mutation in HBV polymerase gene region with nested PCR

Detection of HBV lamivudine-resistant mutants with the method of PCR-RFLP in combination with PCR clone sequencing

Analysis of YMDD Mutants in Hepatitis B Virus Infected Patients with Lamivudine Therapy by Restriction Fragment Length Polymorphism (RFLP) of the PCR Products

A Real-Time PCR Method Formonitoring YMDD Motif Mutations Associated with Lamivudine Resistance in Patients with HBVinfection

Detection and Analysis of the New Kind of G743C and G743A Point Mutation of HBV P Gene in Hepatitis B Virus Infected Patients Resistant to Lamivudine

Rapid and High Throughput Detection of Hbvymdd Mutants with Fluorescence Polarization

Novel Assay of Competitively Differentiated Polymerase Chain Reaction for Screening Point Mutation of Hepatitis B Virus.

P.038 Differences of Ymdd Mutational Patterns, Pre-Core/core Promoter Mutations, Serum Viral Loads in Lamivudine-Resistant Hepatitis B Genotypes B and C

YMDD Variants of HBV DNA Polymerase Gene: Rapid Detection and Clinicopathological Analysis with Long-Term Lamivudine Therapy after Liver Transplantation.

Comparison of PCR-fluorescent-probe assay with DNA sequencing analysis for the detection of Hepatitis B virus YMDD mutation

Application of PCR‐LDR‐nucleic Acid Detection Strip in Detection of YMDD Mutation in Hepatitis B Patients Treated with Lamivudine

Monitoring of the Emergence of Hepatitis B Virus YMDD Variants by Fluorometric Real-Time PCR

Detection and Identification of Emergence of HBV YMDD Motif Mutation During Lamivudine Treatment by Hybridization to an Oligonucleotide Array

Relationship between hepatitis B virus polymerase gene mutation patterns of rtM204I/V and pre-core/basal core promoter mutations

Mutations in Precore and Core Promoter Region of HBV in Patients with Hepatic Failure.